Project Grant R50CA305218
Award Date 9/1/25
Completion Date 8/31/29
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This $204,027 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is supporting the Weill Medical College of Cornell University in expanding single-cell and spatial technologies to link clonal genotypes with phenotypes during cancer evolution. The grant aims to develop advanced single-cell methods that can capture multiple data modalities, including genotypes, transcriptomes, methylomes, and protein expression, to better understand how somatic...
- This federal Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports efforts by a Columbia University researcher to develop and implement NCI-sponsored cancer clinical trials at the NCI-designated Herbert Irving Comprehensive Cancer Center (HICCC). The $193,926 award, with a project period from September 1, 2025 to August 31, 2030, will enable the researcher to: (1) develop novel HICCC investigator-led trials for...
- This federal Project Grant award, valued at $401,829.00 and awarded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports innovative research by Weill Medical College of Cornell University to develop transformative methods for high-throughput single-cell mapping of DNA-binding proteins. The project, titled "Precision Single-Cell Mapping of Chromatin-Associated Protein Activity by Molecular Footprinting to Chart Disruptions to Gene Regulation...
- The U.S. National Cancer Institute (NCI) awarded a $122,032 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Weill Medical College of Cornell University. The grant, with a period of performance from February 1, 2025 to January 31, 2027, will fund research to study the role of aberrant mRNA splicing in cancer cell heterogeneity and its potential as a target for immunotherapeutic strategies. The research aims to utilize advanced computational and single-cell approaches...
- This federal Project Grant award of $702,748 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting research at Weill Medical College of Cornell University to determine the role of neutrophils in anti-tumor immunity and immune-related adverse events associated with T cell-based cancer therapies. The project aims to characterize the gene pathways and tumor-derived factors that define functional subsets of anti-tumorigenic neutrophils, with the goal of...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to Weill Medical College of Cornell University to conduct research on the signal transduction mechanisms that regulate the activity of the p70 S6 kinase 1 (S6K1) protein. The primary objectives are to better understand how the mTOR complex 1 (mTORC1) signaling pathway regulates and coordinates cellular processes to promote cancer cell growth, proliferation, migration,...
- The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $1,625,853 Project Grant to New York University (NYU) on December 13, 2024. The grant will support NYU's research to map and characterize the role of 3D "hubs" - regulatory DNA elements that interact with multiple loci - in the context of T-cell leukemia (T-ALL), early T-cell progenitor leukemia (ETP-ALL), and T-cell lymphoma. The project aims to better define how these 3D chromatin structures are rewired...
- This federal Project Grant award for $802,301, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research by Weill Medical College of Cornell University to investigate the mechanisms that control the bone marrow "niche" environment and its role in expanding mutated blood stem cells that increase the risk of cardiovascular disease and cancer. The research aims to identify signaling pathways that can be targeted to prevent...
- The National Cancer Institute (NCI) awarded a $1,034,176 Project Grant to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) with an award date of August 18, 2025. The grant aims to understand the mechanisms of aberrant RNA splicing and how it drives the development of various hematological malignancies, including myelodysplastic syndrome, chronic lymphocytic leukemia, and acute myeloid leukemia. The research builds on the institution's past...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...